Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Forodesine · 8 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| forodesine HCl | DRUG | 2 x 100mg capsules daily |
| Forodesine 200 mg | DRUG | 2 x 100mg tablets once daily |
| forodesine hydrochloride (BCX-1777) | DRUG | experimental, forodesine oral dose 200 mg administered daily. |
| forodesine hydrochloride | DRUG | - |
Inclusion Criteria: 1. Age 18 years and older 2. Diagnosis of CLL established by peripheral blood and/or bone marrow examination and using the standard diagnostic criteria. 3. Subjects with Rai stage III or IV, or earlier stage requiring therapy as determined by the 1996 National Cancer Institute -...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
Forodesine is an investigational small molecule being studied for the treatment of several blood cancers, including cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL), B-cell acute lymphoblastic leukemia, and T-cell leukemia. It is being developed by BioCryst Pharmaceuticals, Inc. (BCRX) and is currently in Phase 2 clinical development.
Forodesine is a small molecule that targets the enzyme purine nucleoside phosphorylase (PNP). By inhibiting PNP, it disrupts purine metabolism, leading to the accumulation of toxic metabolites that induce apoptosis in malignant T-cells. This mechanism is being investigated for its potential to treat T-cell malignancies such as CTCL and T-cell leukemia.
Forodesine is being developed by BioCryst Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BCRX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with various hematologic malignancies.
Forodesine is currently in Phase 2 clinical development. It has completed multiple Phase 2 trials, including studies in cutaneous T-cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). The drug is not yet approved by the FDA and remains investigational.
Forodesine has been evaluated in several completed clinical trials, including NCT00073944 (Phase 1 in refractory cancer), NCT00095381 (Phase 2 in advanced T-cell leukemia), NCT00501735 (Phase 2 in cutaneous T-cell lymphoma), and NCT00640523 (Phase 2 in chronic lymphocytic leukemia). These trials enrolled a total of 144 patients across multiple countries.
Yes, Forodesine is also known as BCX-1777. In clinical trials, it has been referred to as forodesine hydrochloride (BCX-1777), particularly in earlier studies such as NCT00073944 and NCT00095381. This alternative name is used interchangeably in the literature and trial registrations.